Letrozole Teva (Letrozole)

Letrozole works by selectively inhibiting the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. This inhibition leads to a marked decrease in circulating estrogen, depriving estrogen‑dependent breast cancer cells of a key growth stimulus.

The dosage of Letrozole Teva is individualized by the prescribing clinician based on the patient’s clinical condition, renal and hepatic function, and treatment goals. The prescriber determines the appropriate strength and frequency, which is typically a once‑daily oral regimen.

Letrozole is contraindicated in pregnancy and breastfeeding because it can interfere with normal estrogen‑dependent development. The safety profile in these populations is unknown, and the drug should not be used by women who are pregnant, planning to become pregnant, or nursing.

To order Letrozole Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Letrozole belongs to the aromatase inhibitor class, similar to anastrozole and exemestane. Compared with tamoxifen, another common breast‑cancer therapy, Letrozole provides a more potent reduction in estrogen levels and is generally preferred for postmenopausal patients, whereas tamoxifen is often used in premenopausal women.

Letrozole Teva tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in areas with high humidity.

Letrozole Teva is taken orally as a tablet. The patient should swallow the tablet whole with water, and it may be taken with or without food. Consistency in the timing of each dose each day helps maintain stable drug levels.

Serious risks associated with Letrozole include severe liver injury, osteoporotic fractures, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Patients should also be aware of possible severe allergic reactions and cardiac rhythm disturbances, and report any concerning symptoms promptly.

Letrozole should not be used by premenopausal women, pregnant or breastfeeding individuals, patients with severe hepatic impairment, or those with known hypersensitivity to letrozole or any of its excipients. Caution is also advised for patients with a history of osteoporosis or thromboembolic disease.